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Abstract
Background: Systemic adiponectin is reduced in patients with cardiovascular disease (CVD) and
low adiponectin may contribute to the pathogenesis of atherosclerosis. However, circulating
adiponectin is elevated in type 1 diabetes (T1D) patients, who have also a higher incidence to
develop CVD. Because monocytes play an important role in atherosclerosis, we analysed the
influence of adiponectin on cytokine and chemokine release in monocytes from T1D patients and
controls.
Methods: Systemic adiponectin was determined in the plasma and the high-molecular weight
(HMW) form of adiponectin was analysed by immunoblot. Monocytes were isolated from T1D
patients and controls and the adiponectin-stimulated release of interleukin-6 (IL-6), monocyte
chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) was analysed.
Results: Systemic adiponectin was higher in T1D patients. Immunoblot analysis of the plasma
indicate abundance of HMW adiponectin in T1D patients and controls. IL-6, CCL2 and CXCL8
secretion in response to adiponectin were found induced in monocytes from controls whereas only
IL-6 was upregulated in T1D cells. The induction of IL-6 by adiponectin was abrogated by an
inhibitor of the NFκB pathway.
Conclusion: These data indicate that adiponectin-mediated induction of IL-6, CCL2 and CXCL8
is disturbed in monocytes from T1D patients and therefore elevated systemic adiponectin in T1D
patients may be less protective when compared to controls.
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Background
The adipokine adiponectin (APM) is known to exert anti-
inflammatory and insulin-sensitizing effects [1] but recent
studies also describe proinflammatory activities of APM
[2,3]. APM is highly abundant in human plasma and is
secreted by adipose tissue in inverse relation to the body
mass index [1]. APM circulates in blood as trimers, hex-
amers, and higher molecular weight (HMW) complexes
[4]. A proteolytic cleavage product of adiponectin that
includes its globular head group has also been detected in
human plasma [5]. The biological activity of APM
depends on its high order structure with different oligo-
meric complexes activating different signaling pathways.
HMW-APM activates the NFκB pathway and consequently
induces the secretion of IL-6 in differentiated THP-1 cells
and primary monocytes [2,4]. Besides NFκB, HMW-APM
also activates AMP-activated protein kinase (AMPK) [2]
and stimulation of AMPK by metformin, a drug used in
patients with impaired glucose tolerance, also induces IL-
6 in cardiac fibroblasts [6]. Release of the chemokines
CCL2 and CXCL8 is also stimulated by HMW-APM in
human monocytes and may depend on NFκB activation
[3,7].
Chemokines are molecules that attract cells of the
immune system to the site of inflammation and also
mediate the migration of monocytes to the subendothe-
lium, an early event in the formation of atherosclerotic
lesions. Like CCL2, CXCL8 is produced by a variety of cell
types and is induced by proinflammatory mediators like
endotoxin [8]. Both chemokines attract cells of the
immune system to sites of inflammation and CXCL8 is
unique among these proteins because of its high stability
in-vivo [9]. The best characterized CC chemokine is CCL2
(MCP-1) and several studies suggest that CCL2 is the main
chemokine involved in the recruitment of monocytes
from blood into early atherosclerotic lesions. CXCL8
stimulates the adhesion of monocytes to endothelial cells
and has also been linked to the development of athero-
sclerosis [10].
Whereas circulating adiponectin is reduced in the sera of
patients with type 2 diabetes (T2D) and in patients with
cardiovascular disease (CVD) [1], systemic adiponectin is
elevated in type 1 diabetes mellitus (T1D), that is also
associated with macro- and microvasculature complica-
tions [11,12]. Several studies demonstrate a disturbed
response of T1D monocytes to endotoxin shown by an
altered cytokine and chemokine secretion [13,14].
Because HMW-APM and endotoxin activate NFκB it might
be suggested that T1D monocytes show an altered
response to HMW-APM.
Monocytes are involved in the innate immune response
and the formation of early atherosclerotic lesions. An
altered cytokine and chemokine release from these cells
may contribute to premature atherosclerosis and reduced
immune function in T1D patients [15,16]. Therefore the
influence of HMW-APM on the secretion of the multifunc-
tional cytokine IL-6 and the chemokines CCL2 and
CXCL8 was determined in monocytes of T1D patients and
controls.
Methods
Patients and controls
Monocytes were purified from the blood of 10 female
controls and 10 female T1D patients. The median age of
the controls was 24 years (range 24 – 43) and of the
patients 36.5 years (range 18 – 46). The mean body mass
index (BMI) of controls was 20.6 kg/m2 (range 17.5 –
22.3) and of the T1D patients 22.3 kg/m2 (range 19.5 –
31). Only patients with a known history of T1D and an
established therapy with intensive insulin treatment were
recruited for the study. The median duration of diabetes
was 13.5 years (range 7 – 34). The mean HbA1c was 7.2
% (range 5.7 – 9.5). Patients had no infectious disease
within two weeks before blood was drawn. C-reactive pro-
tein was determined by an ELISA from Anogen (Ontario,
Canada) in the plasma and was 1.94 mg/l (range 0.5 – 5)
in controls and 1.1 mg/l (range 0.7 – 1.6) in T1D. All
women gave informed consent and the study was
approved by the local Medical Ethical Committee.
Reagents
Macrophage SFM medium was from Gibco BRL (Karl-
sruhe, Germany). Recombinant M-CSF, recombinant
human adiponectin, polyclonal adiponectin antibody
and CXCL8 ELISA were from R&D Systems (Wiesbaden-
Nordenstadt, Germany), IL-6 ELISA was from Pierce Bio-
technology (Rockford, Illinois), and CCL2 ELISA was
obtained from Amersham Biosciences (Freiburg, Ger-
many). E. coli derived recombinant human proteins were
used as standard for the IL-6, CXCL8 and CCL2 ELISAs.
Apo E antibody was from Chemicon (Hampshire, U.K.).
Vacutainer CPT were from Becton Dickinson (Franklin
Lakes, NJ). InSolution™ NF-κB Activation Inhibitor was
from Calbiochem (Darmstadt, Germany).
Isolation and culture of primary blood monocytes
Peripheral blood leukocytes were isolated from 16 ml of
whole blood by Vacutainer CPT and monocytes were fur-
ther purified by magnetic separation with CD14 beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of
the isolated monocytes was determined by flow cytomet-
ric analysis and was more than 98%. 500,000 monocytes
were cultivated in 500 μl macrophage SFM medium in 24
well plates with 50 ng/ml M-CSF for 24 h. Subsequently
the medium was replaced. Monocytes were either culti-
vated in 500 μl macrophage SFM medium with M-CSF or
in the identical media supplemented with 10 μg/mlCardiovascular Diabetology 2006, 5:17 http://www.cardiab.com/content/5/1/17
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HMW-APM. Supernatants were collected 24 h later and
used for ELISA.
SDS-PAGE and immunoblotting
The plasma was diluted 1,000-fold in PBS and 10 μl were
separated by SDS-polyacrylamide gel electrophoresis and
were transferred to PVDF membranes (Bio-Rad, Ger-
many). To analyse ApoE either 10 μg cellular lysate or 10
μl of the supernatants were used. Incubations with anti-
bodies were performed in 1% BSA in PBS, 0.1% Tween
overnight. Detection of the immune complexes was car-
ried out with the ECL Western blot detection system
(Amersham Pharmacia, Deisenhofen, Germany).
Statistics
Data are represented as Box Plots indicating the median,
the upper and lower quartile, the largest and the lowest
value in the data set. Data are given as median values and
the range of the values. Statistical differences were ana-
lyzed by two tailed Mann-Whitney U Test and a value of P
< 0.05 was considered as statistically significant.
Results
Systemic adiponectin in the plasma of controls and T1D 
patients
Adiponectin was determined in the plasma of controls
and was found to be higher in the patients. While the con-
trols had 9.8 μg/ml (range 5.6–21.5), the T1D patients
had 18.4 μg/ml (range 7.2–25.4) in their plasma (Figure
1A). The difference is significant with p = 0.04. Immuno-
blots were performed with plasma samples from controls
and T1D patients which was seperated by SDS-PAGE
under non-reducing conditions and HMW-APM was
detected in all plasma samples (Figure 1B). Reducing con-
ditions convert the HMW-APM to two protein subunits
most likely resembling dimeric and trimeric APM (Figure
1C) and both multimers were detected in the plasma of
the controls and T1D patients indicating a similar abun-
dance of HMW adiponectin (Figure 1D).
HMW-APM-induced IL-6 secretion in monocytes from 
controls and T1D patients
IL-6 was determined in the supernatants of monocytes
incubated with or without HMW-APM by ELISA. IL-6 was
elevated in the supernatants of HMW-APM incubated
cells. The median of HMW-APM induced secretion in
monocytes from controls was 64.4 pg/ml (range 11.6–
119.3) and in monocytes isolated from T1D patients 31.9
pg/ml (range 0–81.7) (Figure 2A). Therefore a significant
lower IL-6 release in monocytes from T1D patients (p =
0.01) was observed upon HMW-APM treatment.
HMW-APM-induced CCL2 secretion in monocytes from 
controls and T1D patients
The supernatants described above were also used to meas-
ure CCL2. CCL2 is constitutively secreted by non-stimu-
lated monocytes and its concentration was 1,416 pg/ml
(range 418–6,019) in controls and 1,198 pg/ml (range
208–3,227) in monocytes from T1D patients (Figure 2B)
thus being similar in unstimulated monocytes isolated
from controls or T1D patients. In HMW-APM-treated cells
CCL2 secreted from control monocytes was 1,919 pg/ml
(range 704–7,387) (p = 0.007 vs unstimulated cells) and
from T1D 992 pg/ml (range 191–4,643) (p = 0.08 vs
unstimulated cells) (Figure 2B).
HMW-APM induced CXCL8 secretion in monocytes from 
controls and T1D patients
Furthermore CXCL8 was determined in the supernatants
by ELISA. CXCL8 is already expressed in non-stimulated
monocytes and its concentration was 276,000 pg/ml
(range 78,500–382,000) in controls and 312,250
(82,500–358,000) in monocytes from T1D patients indi-
cating a similar release of this chemokine (p = 0.47) (Fig-
ure 2C). CXCL8 in HMW-APM-activated monocytes from
controls was 335,000 pg/ml (range 91,000 – 610,000) (p
vs control = 0.02) and 213,500 pg/ml (range 77,000–
334,500) in T1D monocytes (p = 0.13) (Figure 2C) and
therefore was not induced by HMW-APM in monocytes
from T1D patients.
Metformin does not induce IL-6 in primary human 
monocytes
Monocytes from three different donors were incubated
with 0.5 mM metformin for 24 h and IL-6 was determined
in their supernatants. Our results demonstrate a similar
release of IL-6 in unstimulated and metformin-treated
monocytes (Figure 3A).
Inhibition of NFκB abrogates HMW-APM stimulated IL6 
release
Monocytes from 2 different donors were incubated with
10 μg/ml HMW-APM alone or in combination with 2.5,
5.0 or 10.0 μM InSolution™ NF-κB Activation Inhibitor
for 24 h. IL-6 secretion in control treated cells was set to
100% and HMW-APM induced IL-6 release was 170%
(range 149–225). Whereas 2.5 μM inhibitor did not sig-
nificantly reduce IL-6 (166%, range 81–224), 5 μM reduce
HMW-APM mediated IL-6 release to 144% (range 60–
173, p = 0.02) and 10 μM reduce APM mediated IL-6
secretion to 116% (range 60–144, p = 0.0004) as is shown
in Figure 3B.
Apolipoprotein E is not altered by HMW-APM
Apolipoprotein E (Apo E) secretion in monocytes is sup-
pressed by endotoxin and therefore the influence of
HMW-APM on intracellular Apo E was also studied. Nei-Cardiovascular Diabetology 2006, 5:17 http://www.cardiab.com/content/5/1/17
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Systemic adiponectin in T1D patients and controls Figure 1
Systemic adiponectin in T1D patients and controls. (A) Systemic adiponectin was determined by ELISA in the plasma of 
10 controls and 10 T1D patients. (B) Immunoblot of plasma adiponectin separated by SDS-PAGE under non-reducing condi-
tions with plasma from controls (C2 to C5) and T1D patients (D2 to D5). (C) Immunoblot of plasma adiponectin separated by 
SDS-PAGE under non-denaturing (-βME) or denaturing conditions (+βME) from control 1 (C1) and T1D patient 1 (D1). (D) 
Immunoblot of plasma adiponectin separated by SDS-PAGE under reducing conditions with plasma from controls (C1 to C4) 
and T1D patients (D1 to D4).Cardiovascular Diabetology 2006, 5:17 http://www.cardiab.com/content/5/1/17
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ther intracellular nor secreted Apo E is altered by HMW-
APM when monocytes from 3 different donors were ana-
lysed and the results from monocytes of 2 donors is
shown (Figure 4) indicating that not all genes that
respond to endotoxin are altered by HMW-APM.
Discussion
Systemic adiponectin was found elevated in T1D patients
[11,12] and this is also the case in the study group inves-
tigated in this work. HMW-APM is currently suggested to
represent the biologic active form of adiponectin [17] and
HMW-APM stimulated IL-6, CCL2 and CXCL8 secretion of T1D and control monocytes Figure 2
HMW-APM stimulated IL-6, CCL2 and CXCL8 secretion of T1D and control monocytes. Monocytes from 10 
controls and 10 T1D patients were cultivated as described in the text. IL-6 (A), CCL2 (B) and CXCL8 (C) were determined in 
the supernatant of cells treated with 10 μg/ml HMW-APM for 24 h. CCL2 (B) and CXCL8 (C) were also determined in unstim-
ulated monocytes.Cardiovascular Diabetology 2006, 5:17 http://www.cardiab.com/content/5/1/17
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was detected in control and T1D plasma when analysed
by immunoblot.
Several studies describe antiinflammatory effects of adi-
ponectin in activated monocytes and E. coli produced full-
length adiponectin at a concentration of 10 μg/ml was
effective in reducing tumor necrosis factor α and IL-6
[18,19]. Full-length human adiponectin produced in a
mouse cell line (10 μg/ml), however, induces IL-6, CXCL8
and CCL2 [2,7] in primary human monocytes whereas
full-length human adiponectin produced in insect cells (1
μg/ml) has antiinflammatory properties [2]. In microvas-
cular endothelial cells, full-length human adiponectin
produced in the mouse cell line also upregulates CCL2
and CXCL8 whereas mesangial cells did not respond even
when 50 μg/ml of adiponectin were used [7]. The recom-
binant globular adiponectin from mammalian cells (10
and 25 μg/ml were tested) did not upregulate CXCL8 and
CCL2 in microvascular endothelial cells and furthermore
could not block full-length adiponectin induced chemok-
ine secretion [7]. A further study describes an induction of
tumor necrosis factor α and IL-6 in macrophages by glob-
ular adiponectin (10 μg/ml) [20]. Adiponectin purified
from human plasma stimulated CXCL8 in activated
HMW-APM does not regulate Apo E Figure 4
HMW-APM does not regulate Apo E. Cellular and 
secreted Apo E was analyzed by immunoblot in monocytes 
treated with PBS as solvent control or HMW-APM and the 
results for monocytes of 2 different donors is shown.
Influence of metformin on IL-6 release and inhibiton of HMW-APM stimulated IL-6 by a NFκB inhibitor Figure 3
Influence of metformin on IL-6 release and inhibiton of HMW-APM stimulated IL-6 by a NFκB inhibitor. (A) 
Monocytes from 3 controls were cultivated with 0.5 mM metformin for 24 h and IL-6 was determined. (B) Monocytes from 2 
different donors were incubated with 10 μg/ml HMW-APM alone or in combination with 2.5, 5.0 or 10.0 μM InSolution™ NF-
κB Activation Inhibitor for 24 h and IL-6 was measured.Cardiovascular Diabetology 2006, 5:17 http://www.cardiab.com/content/5/1/17
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monocytes and inhibited CXCL8 in the presence of apop-
totic cells [3].
The data from the literature indicate that the effects of adi-
ponectin may depend on its high order structure, post-
translational modification and on the activation state of
the monocytes investigated. However, comparative stud-
ies have to be performed to identify the reasons for these
different findings.
In the present study full-length human adiponectin pro-
duced in a mouse cell line was used and IL-6, CCL2 and
CXCL8 were found induced in monocytes isolated from
healthy controls.
When compared to monocytes isolated from controls,
T1D cells show a reduced response to HMW-APM.
Whereas HMW-APM stimulated secretion of IL-6 was
lower in T1D monocytes, HMW-APM did not induce
CCL2 or CXCL8 in T1D cells. Release of IL-6 and CCL2 is
also lower in T1D cells when treated with endotoxin [14].
HMW-APM and endotoxin mediated increase of IL6
depends on the activation of NFκB indicating that NFκB
signaling is partly impaired in T1D monocytes. In con-
trast, CXCL8 is similarily induced in T1D monocytes and
control cells by endotoxin but not stimulated by HMW-
APM in the patients' cells although upregulation of this
chemokine, at least by endotoxin, also depends on NFκB
[8]. Apo E is reduced by endotoxin [14] whereas HMW-
APM did not alter Apo E in human monocytes. Therefore
not all proteins are similarily regulated by endotoxin and
HMW-APM.
IL-6 is higher in the sera of patients with T1D, T2D and in
patients with coronary artery disease [21,22]. Therefore
reduced IL-6 release of T1D monocytes upon stimulation
with HMW-APM may be beneficial in the development of
atherosclerosis. However, impaired IL-6 secretion may
contribute to an ineffective innate immune response and
higher incidence and duration of infections [23] and this
may secondary promote atherogenesis.
In contrast to control monocytes, secretion of CCL2 is not
altered by HMW-APM stimulation of T1D cells. Levels of
CCL2 are increased early in the course of plaque forma-
tion and lead to increased monocyte migration into the
atherosclerotic lesion [24]. Monocytes migrate into the
intima due to a CCL2 concentration gradient that is
formed by endothelial cells and monocytes [25]. Lower
expression of CCL2 by T1D cells may increase this gradi-
ent and enhance migration of monocytes to the endothe-
lium similar to a recent publication where an increase in
CCL2 expression in adipose tissue enhances macrophage
infiltration to this site [26]. Furthermore CCL2 is
decreased in the plasma of T1D patients [27] and dimin-
ished secretion of CCL2 by monocytes may contribute to
reduced plasma levels. The chemokine CXCL8 also acti-
vates monocytes and may recruit these cells to the
endothelium. CXCL8 was found to be reduced by adi-
ponectin purified from human plasma in macrophages
when the cells were cultivated in the presence of apoptotic
cells and was induced in the absence of apoptotic cells or
when endotoxin was added to the macrophages. These
authors suggest that adiponectin is a dual modulator of
innate responses and not an antiinflammatory adipokine
[3].
The current data indicate that HMW-APM signal transduc-
tion pathways are impaired in T1D monocytes. Therefore
elevated circulating adiponectin may be less protective in
T1D patients when compared to healthy individuals.
Conclusion
Taken together, the present study demonstrates that T1D
monocytes have a lower secretion of IL-6 and fail to
induce CCL2 and CXCL8 when treated with HMW-APM.
Therefore elevated systemic adiponectin in T1D patients
may not reduce the risk to develop cardiovascular disease.
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